{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:52:54Z","timestamp":1767145974422,"version":"build-2238731810"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.japh.2025.102489","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:57:18Z","timestamp":1753459038000},"page":"102489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The public health impact of the Rx-to-OTC switch of triptan in Germany: Systematic review and framework analysis"],"prefix":"10.1016","volume":"65","author":[{"given":"Candice Aphroditta","family":"Imanuel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeenah","family":"Atwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7690-6368","authenticated-orcid":false,"given":"Celine","family":"Tabche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.japh.2025.102489_bib1","first-page":"2","article-title":"Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study","volume":"5","author":"Porst","year":"2020","journal-title":"J Health Monit"},{"issue":"10","key":"10.1016\/j.japh.2025.102489_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1055\/s-0038-1673598","article-title":"Therapie der migr\u00e4neattacke und prophylaxe der migr\u00e4ne","volume":"37","author":"Diener","year":"2018","journal-title":"Nervenheilkunde"},{"issue":"11","key":"10.1016\/j.japh.2025.102489_bib3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00228-015-1929-5","article-title":"Use of over-the-counter (OTC) drugs and perceptions of OTC drug safety among German adults","volume":"71","author":"Barrenberg","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.japh.2025.102489_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40122-024-00625-2","article-title":"Rizatriptan as an over-the-counter triptan in the treatment of migraine attacks","volume":"13","author":"G\u00f6bel","year":"2024","journal-title":"Pain Ther"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib5","first-page":"15","article-title":"The treatment of migraine patients with triptans - is there a need for further Rx-to-OTC switches?","volume":"25","author":"Schneider-Ziebe","year":"2020","journal-title":"Gesundheitsokonomie Qual"},{"issue":"3","key":"10.1016\/j.japh.2025.102489_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jval.2018.09.2840","article-title":"Cost-effectiveness of reclassifying triptans in Australia: application of an economic evaluation approach to regulatory decisions","volume":"22","author":"Parkinson","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib7","article-title":"Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2025.102489_bib9","first-page":"97","article-title":"Switch - the German process for moving medicines from prescription to non-prescription status","volume":"23","author":"Kroth","year":"2018","journal-title":"Gesundheitsokonomie Qual"},{"key":"10.1016\/j.japh.2025.102489_bib10","author":"Ridley"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.healthpol.2007.08.006","article-title":"Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?","volume":"86","author":"Shiffman","year":"2008","journal-title":"Health Policy (New York)"},{"issue":"11","key":"10.1016\/j.japh.2025.102489_bib12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMra011080","article-title":"Changing the status of drugs from prescription to over-the-counter availability","volume":"345","author":"Brass","year":"2001","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-019-4219-6","article-title":"Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders","volume":"19","author":"Gauld","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.japh.2025.102489_bib14","author":"Uwe May"},{"key":"10.1016\/j.japh.2025.102489_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2052-3211-8-S1-O5","article-title":"A cost\/benefit analysis of self-care initiatives in the European Union: who gains, who loses?","volume":"8","author":"Renner","year":"2015","journal-title":"J Pharm Policy Pract"},{"issue":"4","key":"10.1016\/j.japh.2025.102489_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/1355819615593302","article-title":"Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries","volume":"20","author":"Gauld","year":"2015","journal-title":"J Health Serv Res Policy"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","article-title":"Medication overuse headache","volume":"9","author":"Ashina","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.japh.2025.102489_bib18","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.japh.2025.102489_bib19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: the SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke","year":"2012","journal-title":"Qual Health Res"},{"key":"10.1016\/j.japh.2025.102489_bib20","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 21: qualitative evidence","author":"Noyes","year":"2024"},{"key":"10.1016\/j.japh.2025.102489_bib22","author":"Cobcroft"},{"key":"10.1016\/j.japh.2025.102489_bib24","author":"Arnold"},{"issue":"12","key":"10.1016\/j.japh.2025.102489_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084088","article-title":"Economic impact of a triptan Rx-To-OTC switch in six EU countries","volume":"8","author":"Millier","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.japh.2025.102489_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-017-2240-4","article-title":"From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006\u20132015: pharmacological perspectives on regulatory decisions","volume":"73","author":"Barrenberg","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.japh.2025.102489_bib28","author":"Stippler"},{"key":"10.1016\/j.japh.2025.102489_bib29","author":"Stippler"},{"issue":"2","key":"10.1016\/j.japh.2025.102489_bib30","first-page":"51","article-title":"Consumer impressions of the safety and effectiveness of OTC medicines","volume":"11","author":"Taylor","year":"2023","journal-title":"Pharm (Basel)"},{"issue":"23","key":"10.1016\/j.japh.2025.102489_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236925","article-title":"Health-Related quality of life in migraine: EQ-5D-5L-Based Study in routine clinical practice","volume":"11","author":"Domitrz","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0972753120929563","article-title":"Migraine disability, quality of life, and its predictors","volume":"27","author":"R","year":"2020","journal-title":"Ann Neurosci"},{"issue":"4","key":"10.1016\/j.japh.2025.102489_bib34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.12286","article-title":"Triptan education and improving knowledge for optimal migraine treatment: an observational study","volume":"54","author":"Baron","year":"2014","journal-title":"Headache"},{"key":"10.1016\/j.japh.2025.102489_bib35","article-title":"Knowledge and attitudes toward over-the-counter medications among pharmacy students: insights from a cross-sectional study in Taif University, Saudi Arabia","volume":"11","author":"Alharthi","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.japh.2025.102489_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/2279-042X.185706","article-title":"Prescription to over-the-counter switches in the United States","volume":"5","author":"Chang","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"10.1016\/j.japh.2025.102489_bib37","first-page":"3","article-title":"Switching drugs from Rx to OTC status\u2013A regulatory perspective","volume":"9","author":"Kartha","year":"2017","journal-title":"J Young Pharm"},{"issue":"9","key":"10.1016\/j.japh.2025.102489_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18094392","article-title":"Impact of pharmacists' interventions and patients' decision on health outcomes in terms of medication adherence and quality use of medicines among patients attending community pharmacies: a systematic review","volume":"18","author":"Rajiah","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/j.japh.2025.102489_bib40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ijpp.12462","article-title":"Community pharmacist-led interventions and their impact on patients' medication adherence and other health outcomes: a systematic review","volume":"26","author":"Milosavljevic","year":"2018","journal-title":"Int J Pharm Pract"},{"key":"10.1016\/j.japh.2025.102489_bib41","first-page":"113","article-title":"Outcomes of pharmacist-led pharmaceutical care interventions within community pharmacies: narrative review","volume":"12","author":"Eldooma","year":"2023","journal-title":"Integr Pharm Res Pract"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"10.1016\/j.japh.2025.102489_bib43","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1001\/amajethics.2021.613","article-title":"How should economic evaluation be used to measure value and set priorities in health care?","volume":"23","author":"Jayawardana","year":"2021","journal-title":"AMA J Ethics"},{"issue":"1","key":"10.1016\/j.japh.2025.102489_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40945-022-00154-1","article-title":"Economic evaluation: a reader's guide to studies of cost-effectiveness","volume":"12","author":"Abbott","year":"2022","journal-title":"Arch Physiother"}],"updated-by":[{"DOI":"10.1016\/j.japh.2025.102923","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000}}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:36:09Z","timestamp":1763768169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1544319125001682"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102489","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The public health impact of the Rx-to-OTC switch of triptan in Germany: Systematic review and framework analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"102489"}}